SAB Biotherapeutics, Inc. (NASDAQ:SABS) Short Interest Update

SAB Biotherapeutics, Inc. (NASDAQ:SABS) saw a large decline in short interest in July. As of July 15th, there was short interest totalling 26,400 shares, a decline of 17.0% from the June 30th total of 31,800 shares. Based on an average daily volume of 16,600 shares, the short-interest ratio is presently 1.6 days. Currently, 0.4% of the shares of the stock are sold short.

SAB Biotherapeutics Trading Down 2.5 %

Shares of NASDAQ SABS traded down $0.07 during trading on Tuesday, reaching $2.70. The company had a trading volume of 2,523 shares, compared to its average volume of 15,643. SAB Biotherapeutics has a 52 week low of $2.36 and a 52 week high of $10.50. The business’s 50 day moving average price is $2.89 and its 200-day moving average price is $4.21. The company has a current ratio of 5.65, a quick ratio of 5.65 and a debt-to-equity ratio of 0.06.

SAB Biotherapeutics (NASDAQ:SABS) last posted its quarterly earnings data on Monday, May 20th. The company reported ($0.54) earnings per share for the quarter, topping the consensus estimate of ($0.98) by $0.44. The firm had revenue of $0.95 million during the quarter. SAB Biotherapeutics had a negative net margin of 1,531.26% and a negative return on equity of 109.90%. As a group, research analysts forecast that SAB Biotherapeutics will post -4.08 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages recently issued reports on SABS. Brookline Capital Management started coverage on shares of SAB Biotherapeutics in a research report on Friday, June 7th. They set a “buy” rating and a $8.00 target price for the company. HC Wainwright reissued a “buy” rating and issued a $6.00 target price on shares of SAB Biotherapeutics in a report on Tuesday, May 21st. Finally, Chardan Capital reaffirmed a “buy” rating and set a $25.00 price target on shares of SAB Biotherapeutics in a report on Tuesday, May 21st.

Hedge Funds Weigh In On SAB Biotherapeutics

Several hedge funds have recently added to or reduced their stakes in SABS. First PREMIER Bank bought a new stake in shares of SAB Biotherapeutics in the 2nd quarter valued at about $60,000. Commodore Capital LP acquired a new stake in SAB Biotherapeutics in the fourth quarter worth $1,259,000. BVF Inc. IL bought a new position in shares of SAB Biotherapeutics during the fourth quarter worth $6,310,000. Finally, RTW Investments LP bought a new position in shares of SAB Biotherapeutics during the fourth quarter worth $6,310,000. Institutional investors and hedge funds own 7.82% of the company’s stock.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.